EUVIMEDOpdag EUVIMED
Crossref

Ursodeoxycholic acid inhibits platelet activation and thrombosis via TREM2: Evidence from mouse models and human studies

Xiaowen Wu, Yulong Zhang, Qingyuan Yang, Liwen Xue, Yifan Guo, Li Li, Changran Liu, Meina Jin, Guanxing Pan, Jianlong Men, Xiongwen Chen, Jianzeng Dong and 2 more

British Journal of Pharmacology · 2026-09 · 183 (18) · 5566-5585

DOI: 10.1111/bph.70567 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-07-01. Written by Xiaowen Wu and 13 co-authors. Institution: School of Pharmacy, Tianjin Medical University, Tianjin, China. Major MEDLINE topics: Ursodeoxycholic Acid, Platelet Activation, Membrane Glycoproteins, Thrombosis. 74 references. Funded by: National Natural Science Foundation of China, Tianjin Medical University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Current antiplatelet therapies effectively prevent thrombosis but are associated with an increased risk of bleeding, highlighting the need for safer alternatives. Ursodeoxycholic acid (UDCA) is a bile acid derivative with an established clinical safety profile, but its effects on platelet function and thrombosis remain poorly defined. Experimental Approach The effects of UDCA on platelet activation were assessed in human and mouse platelets in vitro and ex vivo. Antithrombotic efficacy and bleeding risk were evaluated in murine models of mesenteric arteriole injury and pulmonary embolism. Platelet activity was examined in healthy volunteers following oral administration, and clinical associations were explored in patients with acute coronary syndrome. Ligand–receptor interactions were analysed using molecular docking and surface plasmon resonance, and mechanistic pathways were investigated using genetic and biochemical approaches. Key Results UDCA inhibited platelet activation in both human and mouse platelets and reduced thrombus formation in vivo, with efficacy comparable to clopidogrel but significantly less bleeding. Oral administration suppressed platelet activation in healthy volunteers, and patients with acute coronary syndrome receiving UDCA exhibited lower serum troponin levels. UDCA directly bound to triggering receptor expressed on myeloid cells 2 (TREM2), and its antiplatelet effects were attenuated in TREM2‐deficient platelets. Mechanistically, UDCA enhanced Src homology 2 domain‐containing inositol phosphatase 1 (SHIP1) and suppressed Akt phosphorylation. Conclusions and Implications These findings identify UDCA as a TREM2 agonist with antiplatelet and antithrombotic activity and a favourable bleeding profile, supporting its potential as a safer therapeutic strategy for thrombotic diseases.

Subjects

MeSH terms (MEDLINE)

Ursodeoxycholic AcidPlatelet ActivationMembrane GlycoproteinsThrombosisReceptors, ImmunologicPlatelet Aggregation InhibitorsAnimalsHumansMiceMaleMice, Inbred C57BLDisease Models, AnimalBlood PlateletsMiddle AgedAcute Coronary SyndromeFemale

Author keywords

acute coronary syndromeplatelet activationthrombosistrem2ursodeoxycholic acid

Substances

Ursodeoxycholic AcidMembrane GlycoproteinsReceptors, ImmunologicPlatelet Aggregation Inhibitors

Authors and institutions

  • School of Pharmacy, Tianjin Medical University, Tianjin, China.
  • Department of Medical Laboratory Science, Shanxi College of Medicine, Fenyang, Shanxi, China.
  • Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
  • Internsive Care Unit, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Department of Pharmacy, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Precision Medicine Center, General Hospital of Tianjin Medical University, Tianjin, China.

Funding

  • National Natural Science Foundation of China
  • Tianjin Medical University

Cite

APA

Wu, X., Zhang, Y., Yang, Q., Xue, L., Guo, Y., Li, L., Liu, C., Jin, M., Pan, G., Men, J., Chen, X., Dong, J., Chen, B., & Ding, Z. (2026). Ursodeoxycholic acid inhibits platelet activation and thrombosis via TREM2: Evidence from mouse models and human studies. British Journal of Pharmacology, 183(18), 5566-5585. https://doi.org/10.1111/bph.70567

Vancouver

Wu X, Zhang Y, Yang Q, Xue L, Guo Y, Li L, et al. Ursodeoxycholic acid inhibits platelet activation and thrombosis via TREM2: Evidence from mouse models and human studies. British Journal of Pharmacology. 2026;183(18):5566-5585. doi:10.1111/bph.70567

BibTeX
@article{Wu2026,
  author = {Wu, Xiaowen and Zhang, Yulong and Yang, Qingyuan and Xue, Liwen and Guo, Yifan and Li, Li and Liu, Changran and Jin, Meina and Pan, Guanxing and Men, Jianlong and Chen, Xiongwen and Dong, Jianzeng and Chen, Bing and Ding, Zhongren},
  title = {Ursodeoxycholic acid inhibits platelet activation and thrombosis via TREM2: Evidence from mouse models and human studies},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {18},
  pages = {5566--5585},
  doi = {10.1111/bph.70567}
}
Start for free →